artifici
manipul
antibodi
gene
facilit
product
sever
uniqu
recombin
antibodi
format
highli
import
therapeut
biotechnolog
applic
although
bispecif
antibodi
bsab
new
come
forefront
knowledg
potenti
efficaci
antibodybas
therapeut
expand
next
gener
bsab
develop
due
signific
improv
recombin
antibodi
technolog
review
focus
recent
advanc
particular
focu
improv
format
design
contribut
resurg
bsab
particular
innov
structur
applic
next
gener
pointofcar
poc
devic
applic
low
resourc
environ
antibodi
bispecif
antibodi
belong
class
globular
protein
call
immunoglobulin
produc
b
lymphocyt
deploy
immun
system
identifi
target
foreign
nonself
molecul
structur
antibodi
figur
determin
bind
specif
biolog
activ
antibodi
divers
protein
found
natur
greatest
variabl
amino
acid
sequenc
contain
within
hypervari
region
complementaritydetermin
region
cdr
see
glossari
locat
fv
region
thu
antibodi
cdr
determin
specif
cognat
antigen
fc
region
essenti
mediat
effector
function
includ
antibodydepend
cellmedi
cytotox
adcc
antibodydepend
cellular
phagocytosi
antigen
present
immun
system
degranul
complementmedi
lysi
regul
cell
activ
prolifer
nobel
laureat
milstein
devis
first
becom
freeli
avail
henc
wide
use
method
gener
monoclon
antibodi
mab
howev
extens
antibodi
engin
optim
requir
effect
antibodi
produc
first
antitumor
mab
rituximab
approv
use
worldwid
sinc
mab
achiev
regulatori
approv
therapeut
use
despit
signific
posit
clinic
result
especi
case
hematolog
malign
advers
clinic
outcom
anim
studi
highlight
underli
limit
mab
accordingli
mani
strategi
develop
order
improv
specif
control
function
antibodi
one
import
approach
develop
bsab
review
focus
current
futur
avenu
research
bsab
addit
applic
bsab
diagnost
discuss
critic
assess
glossari
bispecif
antibodi
bsab
antibodyderiv
protein
abil
bind
two
differ
epitop
bispecif
cell
engag
bite
class
bsab
capabl
direct
host
immun
system
complementar
determin
region
cdr
hypervari
region
antibodi
exhibit
high
level
sequenc
divers
involv
antigen
bind
bsab
bsab
antibodyderiv
protein
abil
bind
two
differ
epitop
differ
antigen
first
bsab
produc
oxid
recombin
two
unival
antibodi
prepar
howev
anoth
year
bsab
therapeut
potenti
produc
establish
hybridoma
technolog
major
advanc
pave
way
bsab
develop
bsab
produc
three
main
method
chemic
conjug
involv
chemic
crosslink
ii
fusion
two
differ
hybridoma
cell
line
iii
genet
approach
involv
recombin
dna
technolog
fusion
two
differ
hybridoma
produc
hybridhybridoma
quadroma
figur
secret
heterogen
antibodi
popul
includ
bispecif
molecul
altern
approach
includ
chemic
conjug
two
differ
mab
andor
smaller
antibodi
fragment
oxid
reassoci
strategi
link
two
differ
antibodi
antibodi
fragment
found
ineffici
due
presenc
side
reaction
reoxid
multipl
nativ
disulfid
bond
current
method
chemic
conjug
focu
use
homoor
heterobifunct
crosslink
reagent
recombin
dna
technolog
yield
greatest
rang
bsab
artifici
manipul
gene
repres
divers
approach
bsab
gener
format
past
two
decad
sever
bsab
format
redirect
cytotox
effector
cell
target
cell
play
key
role
diseas
process
induc
cytotox
phagocytosi
present
antigen
directli
suppress
deregul
immun
respons
depend
natur
interact
bsab
target
furthermor
deliv
payload
includ
toxin
drug
prodrug
contrast
agent
bsab
proven
major
therapeut
interest
past
year
due
array
potenti
capabl
also
possess
sever
advantag
characterist
therapeut
develop
includ
design
flexibl
modular
optim
select
activatori
downregul
molecul
oligoreact
deliveri
therapeut
molecul
vast
major
bsab
initi
design
retarget
effector
cell
toward
tumor
cell
varieti
construct
design
retarget
cell
immun
system
bind
trigger
fc
receptor
surfac
effector
cell
bind
cell
receptor
tcr
complex
first
gener
bsab
predominantli
gener
use
hybridhybridoma
chemic
crosslink
despit
signific
biolog
effect
elicit
antibodi
ongo
signific
impact
clinic
cours
diseas
state
issu
associ
first
gener
bsab
includ
difficulti
largescal
product
homogen
batch
lack
efficaci
murin
antibodi
fragment
human
antimous
antibodi
hama
respons
observ
major
treat
patient
addit
fcmediat
side
effect
cytokinereleas
syndrom
thrombocytopenia
leukopenia
subsequ
research
focus
approach
overcom
limit
novel
antibodi
format
advent
recombin
dna
technolog
possibl
amelior
shortcom
associ
tradit
approach
bsab
product
plethora
differ
recombin
bsab
format
exist
figur
rang
whole
igglik
molecul
figur
e
small
recombin
format
figur
tandem
singl
chain
variabl
fragment
molecul
tafv
diabodi
db
singl
chain
diabodi
scdb
variou
deriv
bispecif
tetraval
molecul
produc
use
fcmediat
dimer
possess
two
bind
site
antigen
impart
increas
avid
frequent
approach
produc
tetraval
bispecif
molecul
fusion
singlechain
fv
fragment
c
terminu
antibodi
heavi
chain
substitut
fab
arm
bispecif
singlechain
antibodi
fragment
tandem
scfv
scdb
approach
fuse
two
differ
scfv
n
trend
biotechnolog
novemb
vol
terminu
constant
heavi
light
chain
domain
also
possibl
fuse
second
variabl
heavi
v
h
variabl
light
v
l
domain
heavi
light
chain
antibodi
therefor
lead
product
dualvariabledomain
dvd
antibodi
figur
recombin
strategi
also
use
produc
small
bsab
fragment
common
approach
fusion
two
differ
scfv
molecul
strategi
form
basi
bispecif
cell
engag
bite
develop
cancer
immunotherapi
figur
expans
strategi
fusion
addit
scfv
fragment
molecul
lead
format
trival
trispecif
antibodi
altern
approach
two
bispecif
db
two
bispecif
trival
protein
express
within
cell
produc
test
potenti
agent
pretarget
deliveri
radiolabel
bival
hapten
tumor
express
carcinoembryon
antigen
chain
assembl
antiparallel
manner
form
heterodimer
molecul
scfv
fragment
express
bacteria
known
exist
monomer
dimer
form
exploit
form
db
gener
link
v
h
domain
one
antibodi
v
l
domain
anoth
figur
linker
deliber
short
amino
acid
length
induc
two
domain
pair
complementari
domain
anoth
chain
thu
creat
two
differ
antigenbind
site
scdb
deriv
db
approach
figur
produc
introduc
addit
peptid
linker
join
two
antibodi
fragment
henc
domain
express
singl
polypeptid
chain
although
recombin
product
scfv
fragment
may
circumv
shortcom
associ
hybridhybridoma
approach
face
signific
challeng
certain
form
scfv
variabl
unpredict
express
yield
linker
use
caus
spontan
aggreg
recombin
materi
introduc
shorten
linker
produc
db
alway
guarante
success
linker
induc
deleteri
conform
chang
result
reduct
antibodi
function
overcom
solubilityrel
issu
sever
uniqu
approach
undertaken
stabil
rbsab
singl
domain
antibodi
sdab
occur
natur
repertoir
camelid
cartilagin
fish
figur
f
singl
v
domain
construct
known
v
hh
camelid
vnar
shark
minim
size
kda
addit
demonstr
high
express
level
exhibit
high
stabil
solubl
vitro
made
attract
entiti
bsab
gener
sdab
produc
bacteria
yeast
properti
support
facil
convers
bispecif
format
linkag
two
sdab
direct
two
differ
trend
biotechnolog
novemb
vol
antigen
result
low
molecular
mass
kda
although
advantag
biodistribut
hamper
therapeut
success
due
rapid
clearanc
vivo
renal
filtrat
degrad
posit
attribut
associ
sdab
made
key
point
therapeut
interest
dockandlock
construct
method
involv
homoand
heterodimer
dimer
dock
domain
ddd
human
campdepend
protein
kinas
pka
anchor
domain
ad
akinas
anchor
protein
akap
therefor
fusion
fab
fragment
direct
first
antigen
ad
fusion
fab
fragment
direct
second
antigen
ddd
domain
homodim
subsequ
vitro
assembl
two
protein
prepar
result
trival
molecul
compos
one
fabad
two
fabddd
moieti
figur
furthermor
disulfidestabil
scfv
fuse
c
terminu
igg
light
chain
creat
iggscfv
bsab
figur
express
mammalian
cell
purifi
onestep
protein
chromatographi
format
bsab
exhibit
igglik
stabil
demonstr
igglik
tumor
target
blood
clearanc
vivo
format
suggest
standard
platform
construct
function
bsab
sever
iggscfv
format
describ
literatur
figur
e
monospecif
natur
mab
therapi
may
often
limit
effect
use
complex
human
diseas
cancer
hiv
inflammatori
diseas
infecti
diseas
allerg
disord
multifacet
natur
therapeut
resist
result
engag
upregul
altern
receptor
pathway
current
combin
mab
therapi
undergo
clinic
trial
show
efficaci
diseas
cancer
simultan
engag
target
antigen
although
approach
show
promis
mab
combin
therapi
may
requir
achiev
regulatori
approv
therefor
addit
polyclon
strategi
investig
oligoreact
treatment
complex
diseas
state
rbsab
signific
potenti
applic
multifacet
diseas
therapi
engin
block
engag
multipl
site
singl
target
simultan
site
differ
target
within
singl
therapeut
entiti
addit
payload
deliv
specif
target
cell
fc
effector
engag
recruit
cell
immun
system
bsab
particular
therapeut
interest
strategi
cancer
therapi
predomin
diseas
state
bsab
appli
current
applic
focus
redirect
cytotox
activ
lymphocyt
effector
cell
tumor
target
bind
cell
coreceptor
molecul
addit
major
activ
receptor
natur
killer
nk
cell
mediat
lowaffin
interact
igg
sever
antigen
target
undergon
evalu
major
repres
tumorassoci
antigen
taa
tabl
despit
ongo
develop
variou
increasingli
complex
bsab
design
two
format
bite
triomab
made
substanti
impact
triomab
format
proven
success
due
perform
clinic
trial
approv
catumaxomab
regulatori
agenc
format
current
clinic
trial
list
tabl
bite
combin
uniqu
set
properti
unreport
kind
bsab
box
bite
format
potenti
overcom
sever
limit
factor
relat
biolog
activ
tumordirect
bsab
bite
combin
minim
bind
domain
fv
fragment
two
differ
mab
fuse
togeth
short
flexibl
linker
allow
free
rotat
two
arm
thu
facilit
optim
antibodi
antigen
interact
function
form
link
cell
taa
induc
cell
depend
cytotox
activ
protein
includ
perforin
granzym
independ
presenc
mhc
costimulatori
molecul
protein
enter
tumor
cell
initi
apoptosi
blinatumomab
tabl
bite
current
clinic
trial
treatment
nonhodgkin
lymphoma
acut
lymphoblast
leukemia
antihuman
epitheli
cell
adhes
molecul
epcam
antihuman
tandem
singl
chain
fragment
variabl
tafv
second
bite
test
clinic
trial
first
direct
wide
spectrum
solid
tumor
vitro
test
reconfirm
result
obtain
tumor
cell
line
therebi
demonstr
modular
bite
format
current
test
phase
studi
lung
colorect
gastrointestin
cancer
initi
result
suggest
pharmacokinet
properti
risk
system
activ
associ
might
requir
molecular
develop
order
develop
safe
feasibl
treatment
option
trifunct
antibodi
triomab
intact
igg
molecul
character
uniqu
abil
engag
three
differ
cell
type
typic
tumor
cell
cell
accessori
cell
macrophag
dendrit
cell
nk
cell
fcreceptorexpress
cell
trifunct
antibodi
two
differ
antigenbind
specif
commonli
tumor
antigen
presenc
intact
fc
region
facilit
interact
receptor
trigger
sever
immun
defens
reaction
box
although
trifunct
antibodi
initi
perceiv
unfavor
therapeut
develop
due
retent
fc
effector
function
sever
antibodi
assess
clinic
trial
trion
pharma
freseniu
biotech
develop
first
success
trifunct
antibodi
compos
whole
hybrid
mouserat
igg
molecul
specif
tumorassoci
antigen
ertumaxomab
epcam
catumaxomab
catumaxomab
first
bsab
reach
pharmaceut
marketplac
treatment
malign
ascit
patient
epcamposit
carcinoma
simultan
engag
type
iia
iii
fc
receptor
present
ongo
phase
ii
clinic
trial
catumaxomab
underway
treatment
ovarian
gastric
cancer
lymphomun
trend
biotechnolog
novemb
vol
target
b
lymphocyt
membran
antigen
viabl
target
treatment
b
cell
relat
malign
gener
chemic
heteroconjug
cdspecif
chimer
mab
rituximab
murin
mab
muromonab
differ
catumaxomab
compos
two
whole
immunoglobulin
initi
vitro
studi
demonstr
mediat
effici
specif
lysi
b
cell
line
compar
unarm
cell
cell
line
treat
rituximab
alon
pilot
studi
consist
six
patient
recurr
b
cell
malign
promis
result
indic
therapeut
potenti
phase
clinic
trial
current
underway
evalu
efficaci
patient
relaps
refractori
nonhodgkin
lymphoma
nhl
addit
indic
abil
bsab
bind
simultan
specif
antigen
given
detect
moieti
enabl
function
excel
bifunct
immunoprob
diagnost
assay
figur
associ
advantag
bsab
tradit
mab
includ
design
flexibl
onestep
addit
reagent
compar
tradit
multistep
procedur
obviat
requir
label
reagent
directli
secondari
antibodi
reduc
deleteri
effect
chemic
modif
either
enzym
antibodi
antibodi
extrem
versatil
incorpor
varieti
differ
immunodiagnost
assay
platform
microtit
plate
assay
swab
strip
filter
disk
spinningdisctyp
assay
bsab
attract
assay
simplifi
detect
step
current
use
develop
simpl
rapid
highli
sensit
immunoassay
detect
bacteri
viral
infecti
diseas
cancer
diagnost
vivo
cancer
diagnost
imag
vivo
cancer
diagnost
imag
facilit
insight
molecular
function
characterist
cancer
tissu
permit
target
identifi
assess
sever
differ
type
tumor
bsab
cancer
diagnost
imag
proven
effect
particularli
implement
pretarget
strategi
pretarget
strategi
enhanc
sensit
imag
adapt
abbrevi
ad
adenoviru
met
hepatocyt
growth
factor
receptor
pdgfr
plateletderiv
growth
factor
receptor
ccr
chemokin
cc
receptor
cea
carcinoembryon
antigen
dota
n
n
n
tetraacet
acid
egfr
epiderm
growth
factor
receptor
fap
fibroblast
activ
protein
hmwmaa
high
molecular
weight
melanomaassoci
antigen
igfr
insulinlik
growth
factor
receptor
ltbr
leukotrien
b
receptor
mucin
psca
prostat
stem
cell
antigen
psma
prostat
specif
membran
antigen
sap
secretori
aspartyl
proteinas
tnfrelat
apoptosi
induc
ligand
vegfr
vascular
endotheli
growth
factor
receptor
trend
biotechnolog
novemb
vol
elimin
background
nois
consequ
untarget
radioact
reduc
unintend
toxic
strategi
bsab
design
bind
target
antigen
radiometalchel
haptenpeptid
complex
effector
molecul
pretarget
approach
twostep
imag
process
bsab
inject
initi
excess
antibodi
clear
circul
follow
inject
monodival
radiolabel
hapten
anim
model
experi
shown
bsab
capabl
equival
tumor
uptak
compar
convent
radiolabel
antibodi
minimum
accret
within
matter
minut
rather
sever
hour
day
addit
radionucleotid
clear
rapidli
circul
tissu
retent
kidney
liver
low
positron
emiss
tomographi
pet
imag
approach
use
label
hapten
pretarget
bsab
howev
visual
small
malign
lesion
remain
problemat
improv
abil
imag
lesion
altern
strategi
combin
pretarget
highli
specif
highact
radiotracerlabel
polym
bsab
complex
util
pretarget
human
prostat
cancer
xenograph
scid
mice
complex
consist
intact
antidiethylenetriaminepentaacet
acid
dtpa
antibodi
fablink
bombesin
bom
coupl
via
thioether
bond
bombscx
bombsfcx
result
indic
radiolabel
polym
accumul
pretarget
site
enabl
visual
cancer
lesion
small
mm
addit
metastat
melanoma
lesion
lung
mice
imag
bsab
tcdspl
polylysin
polym
conjug
dtpa
succinyl
label
tc
use
bsab
cancer
imag
significantli
enhanc
qualiti
reliabl
techniqu
furthermor
atherosclerot
lesion
small
mm
success
imag
apolipoprotein
e
apo
knockout
mice
use
surrog
antigenco
polystyren
bead
pretarget
bsab
f
ab
f
ab
within
anim
model
bsab
proven
superior
mab
term
specif
sensit
signal
intens
maintain
minim
signal
background
infectiousdiseasecaus
agent
includ
bacteria
virus
parasit
fungi
present
decad
vaccin
world
health
organ
attribut
million
death
annual
infecti
diseas
signific
socioeconom
burden
societi
global
healthcar
system
use
surveil
measur
control
spread
infecti
diseas
reliant
earli
detect
tuberculosi
tb
caus
highli
resist
bacterium
mycobacterium
tuberculosi
particularli
affect
weak
immun
system
exampl
individu
infect
hiv
although
infect
asymptomat
latent
one
ten
infect
eventu
progress
activ
diseas
untreat
kill
infect
report
million
case
tb
million
death
worldwid
rapid
sensit
specif
inexpens
tb
diagnost
poc
set
consider
valu
import
tb
control
current
method
detect
includ
sputum
smear
microscopi
ssm
bacteri
cultur
facilit
earli
diagnosi
bacteri
cultur
method
consid
gold
standard
tb
diagnosi
howev
week
higher
efficaci
tumor
cell
lysi
rel
format
monoclon
igg
antibodi
induc
target
cell
elimin
unstimul
peripher
cell
without
need
cell
costimuli
cell
preactiv
regimen
strictli
target
cell
depend
polyclon
activ
cell
high
protein
stabil
homogen
cytotox
cell
highli
cytotox
potenti
abund
searchanddestroy
function
potent
killer
cell
human
bodi
capabl
effect
induc
tumor
cell
lysi
apoptosi
accessori
cell
target
elimin
tumor
cell
process
phagocytosi
apoptosi
addit
abil
releas
cytokin
stimul
action
cell
dendrit
cell
capabl
induc
longlast
immun
cancer
tumor
process
present
tumor
cell
tumor
cell
deriv
materi
immun
system
trend
biotechnolog
novemb
vol
requir
obtain
result
develop
molecular
assay
includ
interferon
gamma
releas
assay
igra
nucleic
acid
amplif
naa
earli
detect
improv
approach
requir
signific
expertis
infrastructur
consequ
suit
resourcelimit
area
lipoarabinomannan
lam
import
nonprotein
antigen
bacteri
cell
wall
present
differ
bodi
fluid
tbinfect
patient
bispecif
mab
specif
toward
lam
antigen
report
molecul
horseradish
peroxidas
hrpo
develop
hybridhybridoma
technolog
bsab
incorpor
simpl
low
cost
immnuoswabbas
assay
detect
lam
antigen
limit
detect
assay
spike
synthet
lam
ngml
bovin
urin
ngml
rabbit
serum
ngml
salin
bacteri
lam
tuberculosi
found
ngml
rabbit
serum
assay
evalu
use
clinic
serum
sampl
collect
tb
patient
posit
seven
neg
term
antilam
antibodi
titer
assay
exhibit
specif
sensit
confid
interv
parallel
comparison
laboratori
cultur
addit
good
specif
visual
result
obtain
within
h
sampl
collect
immunoassay
also
evalu
anoth
format
test
sensit
assay
use
biotinyl
mab
transform
assay
bispecificbas
format
monoclonalbas
format
reduc
sensit
assay
use
bsab
first
kind
detect
tb
antigen
immnuoswab
assay
provid
enhanc
sensit
specif
report
assay
particularli
suit
resourcelimit
area
rapid
tool
detect
tb
resourc
constrain
laboratori
set
hepat
b
signific
health
concern
viral
hepat
lead
caus
liver
cancer
commonli
result
liver
transplant
hepat
b
viru
surfac
antigen
hbsag
key
screen
target
detect
infect
individu
current
approach
hbsag
screen
reli
laboratorybas
elisa
test
novel
agglutin
test
hepat
b
infect
use
antihbsag
antihuman
erythrocyt
bsab
db
format
develop
phage
display
select
scfv
red
blood
cell
hbsagspecif
librari
human
blood
sampl
clinic
specimen
agglutin
observ
sampl
contain
hbsag
specif
test
show
sensit
agglutin
kinet
hbsag
concentr
depend
high
viral
load
lead
agglutin
min
although
assay
specif
sensit
equival
limit
detect
compar
elisa
differ
oper
within
observ
hbsag
concentr
rang
activ
infect
individu
ngml
mgml
primari
poc
screen
tool
simpl
agglutin
test
power
approach
assist
rapid
screen
hepatitisbinfect
individu
escherichia
coli
e
coli
consid
seriou
human
pathogen
associ
bloodi
diarrhea
hemorrhag
coliti
hemolyt
urem
syndrom
hu
current
method
detect
e
coli
food
water
focu
enrich
microbi
cultur
may
take
h
identifi
organ
techniqu
focu
molecular
method
pcr
despit
sensit
rapid
result
retriev
capabl
techniqu
limit
requir
isol
dna
sampl
sensit
rapid
reliabl
diagnost
techniqu
identif
e
coli
essenti
appropri
detect
manag
prevent
diseas
outbreak
develop
highli
sensit
bsabbas
assay
e
coli
water
sampl
hybridoma
secret
mab
specif
e
coli
whole
bacteria
e
coli
lipopolysaccharid
lp
fuse
antihrpo
mabsecret
hybridoma
gener
quadroma
result
bsab
incorpor
sandwich
elisa
allow
rapid
onestep
detect
e
coli
assay
anti
coli
mab
use
captur
reagent
enrich
bacteria
surfac
follow
bsab
mediat
detect
detect
sensit
assay
determin
cfuml
tap
water
lake
water
appl
juic
respect
microtiterplatebas
assay
mark
improv
sensit
e
coli
achiev
use
immunofilt
immunomagnet
elisa
format
detect
diagrammat
represent
gener
assay
format
bispecif
antibodi
bsab
base
immunoassay
captur
monoclon
antibodi
immobil
solid
surfac
bind
specif
epitop
cognat
antigen
present
test
sampl
upon
addit
correspond
bsab
one
arm
bind
specif
epitop
antigen
arm
bind
report
molecul
horseradish
peroxidas
hrpo
convert
subsequ
ad
substrat
quantifi
signal
color
product
adapt
trend
biotechnolog
novemb
vol
limit
cfuml
cfuml
respect
addit
specif
assay
confirm
detect
bacteri
strain
salmonella
pseudomona
nonpathogen
e
coli
novel
bsabbas
assay
high
specif
low
background
rapid
ultrasensit
major
advantag
assay
comparison
current
assay
remov
requir
amplif
step
bordetella
pertussi
b
pertussi
caus
bacterium
pertussi
whoop
cough
affect
individu
adolesc
age
estim
pertussisrel
death
children
despit
avail
vaccin
becom
major
health
concern
recent
year
estim
suggest
million
case
pertussi
develop
countri
similar
mani
bacteri
infect
earli
detect
critic
order
prevent
spread
infect
ensur
correct
treatment
infect
individu
current
two
method
detect
bacterium
first
requir
clinic
nasopharyng
swab
aspir
sampl
cultur
day
second
method
involv
use
fluoresc
label
mab
direct
antigen
lp
molecul
present
outer
membran
b
pertussi
assay
limit
regard
sampl
oper
train
sensit
restrict
use
resourceconstrain
locat
molecular
velcro
sandwich
assay
detect
b
pertussi
found
use
analysi
clinic
sampl
immunochem
structur
studi
serolog
character
b
pertussi
lp
bsab
produc
fusion
antib
pertussi
lp
mabsecret
hybridoma
antihrpo
mabsecret
hybridoma
antilpsspecif
mab
capabl
bind
heatkil
b
pertussi
buffer
sampl
matrix
spike
nasopharyng
aspir
assay
prove
highli
sensit
lower
limit
detect
cfu
interestingli
bind
b
pertussi
antib
pertussi
lp
mabcoat
solid
phase
found
irrevers
despit
signific
wash
suggest
assay
work
form
velcro
molecular
assay
immunoassay
achiev
ultrasensit
detect
b
pertussi
due
avail
multipl
lp
molecul
bacteri
surfac
bsab
bind
addit
facilit
eas
use
rapid
detect
immunoassay
test
immunoswab
format
permit
poc
detect
b
pertussi
clinic
set
staphylococcu
aureu
thermonucleas
tnase
aureu
frequent
caus
wound
infect
among
hospit
patient
studi
suggest
present
infect
leg
ulcer
major
biomed
problem
chronic
wound
heal
continu
emerg
antibioticresist
speci
becom
major
health
concern
novel
fluorescencebas
immunoassay
enabl
qualit
detect
aureu
tnase
confirm
presenc
aureu
vitro
rhodamin
fluoresceinlabel
hemocyanin
megathura
crenulata
klh
prepar
immunoconjug
contain
sensit
fluoresc
report
moieti
bsab
specif
quench
fluoresc
report
conjug
bound
tnase
target
antigen
produc
use
cell
fusion
techniqu
studi
two
klhfluorophoretnasespecif
antibodi
seri
gener
member
seri
specif
epitop
either
klh
fluoresc
moieti
report
conjug
decreas
fluoresc
emiss
intens
nm
rhodamin
fluorescein
conjug
respect
analyz
bsab
seri
quench
observ
upon
antibodyantigen
bind
increas
fluoresc
intens
observ
upon
tnase
bind
demonstr
antibodi
higher
affin
bacteri
antigen
fluoresc
report
specif
assay
aureu
also
test
use
pseudomona
aeruginosa
lp
antigen
control
demonstr
variat
fluoresc
quench
effect
exceed
preliminari
investig
suggest
highli
sensit
assay
potenti
applic
biolog
specimen
limit
risk
fals
posit
result
sever
acut
respiratori
syndrom
sar
sar
seriou
form
pneumonia
affect
peopl
worldwid
spread
countri
across
five
contin
outbreak
sar
coronaviru
sarscov
respons
agent
transmit
wild
anim
human
popul
delay
identif
viru
aid
contagion
sar
viru
detect
human
rtpcr
indirect
fluoresc
assay
detect
antisarscov
antibodi
bodi
fluid
isol
sarscov
clinic
sampl
viral
cultur
time
consum
tediou
insensit
therefor
pcrand
antibodybas
detect
method
predomin
techniqu
adopt
surveil
highli
sensit
rapid
bsabbas
immunoswab
assay
develop
earli
detect
sarscov
assay
superior
tradit
monoclon
elisabas
assay
detect
viral
antigen
nucleoplasmid
protein
np
three
differ
mab
recogn
variou
epitop
np
antigen
antihrpo
mab
util
gener
antisarscov
np
antihrpo
bsab
immunoswab
assay
show
np
detect
limit
pgml
salin
pgml
pig
nasopharyng
aspir
pgml
rabbit
serum
thu
demonstr
bispecif
detect
approach
superior
term
sensit
specif
immunoswab
assay
facilit
rapid
detect
min
robust
potenti
permit
screen
numer
infect
individu
within
short
period
time
henc
assist
contain
viral
infect
furthermor
target
sarscov
spike
protein
maband
bsabbas
assay
identifi
sar
infect
individu
also
demonstr
bsab
detect
reagent
could
improv
sensit
assay
ngml
although
exampl
demonstr
util
bsab
diagnost
applic
sever
shortcom
relat
use
quadroma
includ
yield
format
uniform
purif
advent
recombin
format
consider
valu
overcom
limit
anticip
bsab
format
therapeut
arena
meaning
appli
diagnost
develop
next
gener
diagnost
devic
poc
decentr
age
care
applic
demand
superior
diagnost
reagent
bsab
stabl
larg
big
pharmaceut
compani
invest
us
billion
bsab
sinc
frontrunn
yet
clearli
emerg
increas
confid
bsab
past
year
result
plethora
bsab
format
combin
highli
innov
molecular
biolog
approach
momentum
gain
clinic
success
prompt
emerg
addit
format
mani
case
may
prove
ineffect
therapeut
applic
result
high
attrit
rate
howev
therapeut
arena
seen
signific
advanc
bsabbas
agent
culmin
singl
bsab
achiev
regulatori
approv
bsab
catumaxomab
extend
far
beyond
tradit
igg
format
access
truli
uniqu
function
mani
origin
groundbreak
approach
requir
similar
develop
human
mab
therapi
efficaci
safeti
simultan
engag
multipl
diseas
target
take
consider
research
potenti
consider
time
show
marketplac
domin
current
clinic
trial
progress
larger
number
entiti
expect
enter
clinic
evalu
futur
still
unclear
smart
retarget
strategi
success
bsab
back
hot
stock
present
due
real
potenti
signific
impact
human
diseas
treatment
manag
although
next
big
blockbust
therapi
may
well
bsab
applic
construct
diagnost
attract
altern
current
strategi
real
potenti
pave
way
improv
nextgener
diagnost
applic
lowresourc
poc
set
bsab
simpl
immunodiagnost
test
applic
set
assist
ensur
test
meet
assur
principl
regardless
applic
common
issu
need
address
box
includ
manufactur
scale
stabil
issu
relat
immunogen
pharmacokinet
biodistribut
particular
concern
therapeut
bsab
tale
move
beyond
two
specif
chapter
vastli
improv
therapeut
applic
also
significantli
impact
current
diagnost
challeng
multitud
bsab
format
provid
compar
preclin
inform
triomab
bite
sdab
way
forward
human
therapeut
pauciti
diagnost
bispecif
improv
singl
bispecif
format
come
fore
therapeut
arena
bispecif
antibodi
deliv
superior
simplifi
diagnost
applic
low
resourc
set
simplif
assay
captur
andor
detect
step
trend
biotechnolog
novemb
vol
